Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET, to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The call will provide insights into the company's financial performance and business updates, supported by the ImmTOR™ platform aimed at developing tolerogenic therapies for autoimmune diseases and gene therapies. Interested parties can join the call via phone or access the archive through the company's website.
- None.
- None.
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.
Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 8768458. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
What date is Selecta Biosciences holding its financial results call?
What financial period will Selecta Biosciences discuss during the call?
How can investors access the Selecta Biosciences conference call?
Where can I find the archived webcast of the Selecta Biosciences call?
